SAB Biotherapeutics Inc. (SABS)
SABS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1833214/000183321426000003/0001833214-26-000003-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SABS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001833214 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | $13.3M |
| Operating income | -$49.0M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $10.5M |
| Total assets | $172.8M |
| P/E (computed) | 20.4× |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $14.4M cash; operating cash flow -$13.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 90,088,831 (2026-11-02); 47,606,851 a year earlier; 52,319,156 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-01-05 | Source 2024-01-05 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-10-22 |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$22.3M | -$13.0M | $14.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$22.5M | -$9.8M | $8.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$18.9M | -$14.3M | $20.5M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$16.9M | -$16.8M | $10.5M | $0 | $0 | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | Not filed | $45.4M | -$13.0M | $29.4M | $0 | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$10.1M | -$7.2M | $3.7M | $0 | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$5.2M | -$7.8M | $5.6M | $139K | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | $115K | -$11.4M | -$9.5M | $8.9M | $552K | $1.3M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-21 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 436 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.3% |
| 1 month | +10.4% |
| 3 months | -21.1% |
| Year to date | -20.9% |
| 1 year | -4.5% |
| From 52-week high | -35.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics Inc. | $3.23 | +12.54% | $265.0M |
| DTIL | Precision BioSciences Inc. | $7.28 | -3.77% | $277.6M |
| OCGN | Ocugen Inc. | $0.7730 | -6.62% | $262.3M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier